CareONE Concierge Launches Innovative Alzheimer's Device Study
In a significant advancement in Alzheimer's research, CareONE Concierge has announced its latest clinical study evaluating a cutting-edge wearable device specifically designed to tackle cognitive issues related to Alzheimer’s disease. This initiative aims to provide new hope for the millions affected by this condition, marking a potential turning point in dementia treatment.
The Study Details
The newly introduced study will utilize the TEMT-RF cap from NeuroEM Therapeutics, a novel non-invasive device that has recently received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA). This device operates on the principle of Transcranial Electromagnetic Treatment using Radio Frequencies (TEMT-RF). It delivers electromagnetic waves closely resembling cell phone signals to break apart harmful protein clusters that contribute to cognitive decline, such as beta-amyloid and tau proteins.
Alzheimer’s disease currently impacts approximately 7 million Americans, a number anticipated to rise to 13 million by 2050, illustrating the urgent need for effective treatments. Traditional therapies have often focused solely on alleviating symptoms rather than addressing the root causes of cognitive deterioration. The TEMT-RF technology aims to reverse this trend by potentially restoring brain function at a fundamental level.
Expert Insights
Peter Bechtel, the CEO of CareONE Concierge, expressed optimism regarding the impact of the study, stating, "We all know friends and family members who have been affected by Alzheimer's or dementia. This study represents a potential turning point in the fight against these debilitating conditions, offering participants the chance to try a state-of-the-art, non-drug therapy."
Participants for the study will specifically be individuals diagnosed with mild to moderate Alzheimer's-related dementia. The protocol requires them to wear the device for one hour, two times a day, while also undergoing cognitive assessments throughout the study period.
Dr. Edward Goodwin, Chief Scientist at NeuroEM, highlighted the scientific significance of the TEMT-RF device, stating, "Our research has indicated that TEMT-RF can potentially influence the biological processes linked to Alzheimer's. This study will provide valuable real-world data on the device's effects on cognitive health."
A Collaborative Vision
Chuck Papageorgiou, CEO of NeuroEM Therapeutics, emphasized the importance of innovative partnerships to advance cognitive health technologies. "With the growing number of Alzheimer’s cases, research initiatives like this are essential in helping us unlock the full promise of TEMT-RF. Together, we can forge a path towards a future where memory loss is not an unavoidable aspect of aging."
CareONE Concierge is currently seeking eligible candidates for participation in the study. Interested individuals can obtain further information or apply by contacting them via email or through their website at
www.BestMindForMe.com.
About CareONE Concierge
CareONE Concierge is dedicated to providing transformative healthcare solutions tailored to the needs of patients, providers, and healthcare systems. The company works diligently to enhance patient outcomes while improving financial health and quality metrics for healthcare systems. For further details, visit their website at
www.careone-concierge.com.
About NeuroEM Therapeutics
NeuroEM Therapeutics is at the forefront of developing and clinically testing bioengineered technologies aimed at reversing cognitive decline in Alzheimer’s and related neurodegenerative diseases. With a strong foundation of research conducted at the University of South Florida, the company has pioneered a groundbreaking wearable device designed for use at home, leveraging patented TEMT-RF technology. Explore more at
neuroem.com.